Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52448 | 0.87 | GRM2 (0.44) | NAMPTGRM2GAAL3MBTL1BRD4 | |
| SCHEMBL27679076 | 0.84 | DRD4 (0.39) | NAMPTGRM2TP53ROCK2DRD2 | |
| SCHEMBL970934 | 0.82 | ALDH1A1 (0.42) | NAMPTGRM2GAAL3MBTL1BRD4 | |
| SCHEMBL973927 | 0.82 | BRD4 (0.42) | NAMPTBRD9BAZ2BBAZ2ATP53 | |
| Acetic Acid SCHEMBL974712 | 0.82 | ALDH1A1 (0.40) | NAMPTGRM2GAAL3MBTL1BRD4 | |
| Hydrochloric Acid SCHEMBL16564426 | 0.81 | ALDH1A1 (0.41) | NAMPTGRM2GAAL3MBTL1BRD4 | |
| SCHEMBL15780846 | 0.74 | MEN1 (0.43) | TP53GAAPOLB | |
| SCHEMBL24999627 | 0.74 | GRM2 (0.49) | NAMPTGRM2GAAL3MBTL1 | |
| SCHEMBL29769069 | 0.74 | GRM2 (0.49) | NAMPTGRM2GAAL3MBTL1 | |
| SCHEMBL24619900 | 0.74 | IGF1R (0.48) | NAMPTGRM2GAAL3MBTL1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225825-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20110015400-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-1723140-B1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1723140-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005095385-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225825-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | CMA1, TPSAB1, TPSB2 | NAMPT 560/4885BRD9 3335/4885BAZ2B 4538/4885 |
| US-20110015400-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | CMA1, TPSAB1, TPSB2 | NAMPT 560/4885BRD9 3335/4885BAZ2B 4538/4885 |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | CMA1, TPSAB1, TPSB2 | NAMPT 560/4885BRD9 3335/4885BAZ2B 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.